BeOne Medicines AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Basel, Basel-Stadt and currently employs 11,075 full-time employees. BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. The company is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Follow-Up Questions
Who is the CEO of BeOne Medicines AG?
Mr. John Oyler is the Co-Founder of BeOne Medicines AG, joining the firm since 2010.
What is the price performance of ONC stock?
The current price of ONC is $311.86, it has decreased 0% in the last trading day.
What are the primary business themes or industries for BeOne Medicines AG?
BeOne Medicines AG belongs to Biotechnology industry and the sector is Health Care
What is BeOne Medicines AG market cap?
BeOne Medicines AG's current market cap is $31.4B
Is BeOne Medicines AG a buy, sell, or hold?
According to wall street analysts, 7 analysts have made analyst ratings for BeOne Medicines AG, including 2 strong buy, 11 buy, 1 hold, 0 sell, and 2 strong sell
